Liquid liver biopsy


Background: The definitive diagnostic test for nonalcoholic steatohepatitis (NASH) is liver biopsy, which carries risks and cannot be used for frequent monitoring. There is no single non-invasive method that can accurately and simultaneously capture steatosis, inflammation, hepatocyte ballooning and fibrosis, the four major pathologic components assessed by biopsy. We show that large scale proteomics has promise as an alternative to liver biopsies in clinical trials or longitudinal studies of NASH.

Methods: Using modified-aptamer proteomics, we scanned ~5,000 proteins in each of 2,852 serum samples from the NASH CRN*, including 636 participants from a natural history cohort and longitudinal samples from the PIVENS (pioglitazone, vitamin E and placebo) and the FLINT (obeticholic acid and placebo) clinical trials, for a total of ~15 million protein measurements. Liver biopsy results were modeled with measured proteins using machine learning methods independently for each biopsy component.

Results: Results for the four protein models in training/paired validation were: fibrosis (AUC 0.92/0.85); steatosis (AUC 0.95/0.79), inflammation (AUC 0.83/0.72), and ballooning (AUC 0.87/0.83). A concurrent positive score for steatosis, inflammation and ballooning predicted the biopsy diagnosis of NASH with an accuracy of 73%. When applied longitudinally, model scores predicted decreasing biopsy scores in the active groups vs. stable for placebo and differential pharmacodynamic effects were evident on each model component.

Conclusions: Serum protein scanning is the first technique to capture four components of the liver biopsy individually and noninvasively. The four models were sufficiently sensitive and precise to characterize the time-course and extent of three drug mechanisms. Concurrent positive results from the protein models had performance characteristics of “rule-out” tests for diagnosis of NASH. These tests may assist in new drug development and medical intervention decisions.

Share with colleagues

More posters

PosterLatest research shows benefit of non-invasive, high-plex protein profiling for liver disease

Learn about using high-plex, aptamer-based protein profiling for NASH research through these three SomaLogic assets. Watch one webinar and download two posters that each highlight NASH research.

Learn more

PosterProteomic Indicators of Metabolic Health in Diabetes and Social Deprivation

Understanding the health impacts of socioeconomic deprivation (SED) and its interaction with type 2 diabetes is important for patient care and effective public health initiatives. Large-scale proteomic profiling using aptamer-based technology to measure 7,000 proteins has facilitated the development of blood-based proteomic signatures for 11 cardiometabolic SomaSignalTM Tests (SST)

Learn more

PosterHeritability, pQTLs, and environmental influence on proteins involved in age, cardiovascular risk, and glucose tolerance using the SomaScan® Assay

Protein quantitative trait locus (“pQTL”) studies identify genetic variants that are statistically associated with protein levels. Results from the growing number of pQTL studies can be combined with genome-wide association studies to identify proteins that underlie the genetic risk of disease, thus revealing the mechanisms of disease and potential drug targets.

Learn more

Explore posters in our interactive viewer